Phase 1 Lupus Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For people with Systemic Lupus Erythematosus (SLE) — a disease where the immune system attacks the body:
- You have been diagnosed with SLE based on specific medical guidelines (2019 ACR/EULAR criteria)
- Certain specific antibodies related to SLE were found in your blood during screening
- Your current treatments (steroids and immune-suppressing medicines) have not worked well enough, or you cannot tolerate them
- Your SLE is currently active at the time of screening
For people with Inflammatory Myopathy (IIM) — a condition causing muscle inflammation:
- You have been diagnosed with IIM based on specific medical guidelines (2017 ACR/EULAR criteria)
- Your IIM is severe and has not responded to previous treatments
- Steroids and immune-suppressing medicines have not worked well enough for you
- Your disease is currently active
For people with Systemic Sclerosis (SSc) — a disease that causes hardening of the skin and can affect organs:
- You have been diagnosed with SSc based on specific medical guidelines (2013 ACR/EULAR criteria)
- Your previous treatments have not worked well enough, or you cannot tolerate them
- Your SSc is getting worse and affects your skin and/or lungs
For people with Rheumatoid Arthritis (RA) — a condition causing joint inflammation:
- Your RA has been difficult to treat
- You have been diagnosed with RA based on specific medical guidelines (2010 ACR/EULAR criteria)
- Your RA is currently active at screening and at the start of the trial
- Standard treatments have not worked well enough, or you cannot tolerate them
Who may not be able to join:
For all participants:
- You have another systemic autoimmune disease (a condition where the immune system attacks multiple parts of the body)
- You are pregnant or currently breastfeeding
- You have active Hepatitis B, Hepatitis C, or HIV
- You have a history of cancer
- You have an infection that is active or not well controlled
- You have had certain heart or blood vessel problems in the 6 months before screening (confirm with trial site)
- You have previously received CAR-T cell therapy (a type of immune cell treatment)
- You have significant lung problems
- Your organs (such as kidneys or liver) are not functioning well enough (confirm with trial site)
- You have an active and serious condition affecting your brain or nervous system
Additionally, for people with SLE:
- Your lupus was caused by a medication, or you have another autoimmune disease alongside SLE
Additionally, for people with IIM:
- You have a different type of muscle disease that is not IIM
- You have severe, lasting muscle damage
Additionally, for people with SSc:
- You have high blood pressure in the arteries of your lungs caused by SSc that requires ongoing treatment to control
- Your SSc is getting worse very rapidly, or you have a history of serious kidney disease related to SSc
Additionally, for people with RA:
- You have another autoimmune disease alongside your RA
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Phone: 855-907-3286
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
3 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of participants with treatment-emergent adverse events (TEAEs); Number of participants with serious AEs (SAEs); Number of participants with AEs of special interest (AESIs); Number of participants with laboratory abnormalities; Number of participants with Dose-Limiting Toxicities (DLTs); Number of participants with DLTs that occur during the DLT evaluation period
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.